Ocular Therapeutix, Inc.
NASDAQ:OCULBiotechnology
-$0.11 today
- Market cap
- $1.29B
- Beta
- 0.90
- P/E (TTM)
- -7.3
- EPS (TTM)
- -$1.30
Volume 3.08M
Average 3.00M
Financial health
Ocular Therapeutix, Inc. financial health
Start with the overall verdict and the rule-based risk checks for OCUL, then work through liquidity, debt, balance-sheet quality, and claims on cash.
Financial health snapshot
Debt service and balance sheet cushion look healthy, even if some working-capital ratios deserve context.
Cash & Investments
$668.31M
Debt Cushion
$588.85M
Current Ratio
14.8x
Interest Coverage
Not available
Risk checks
4 of 10 checks flagged
Interest coverage
-25.8×
Passes when: Operating income is at least 1.5 times interest expense.
Debt repayment from cash flow
Negative FCF
Passes when: Free cash flow could repay all debt within 5 years.
Debt growth versus revenue growth
7.5% vs. 0.2%
Passes when: Over three years, debt growth is no more than 5 percentage points above revenue growth.
Share dilution
+25.2% per year
Passes when: Diluted share count grows no more than 2% per year.
Positive equity
Positive
Passes when: Shareholders’ equity is above zero.
Short-term liquidity
14.8×
Passes when: Current assets are at least 1 times current liabilities.
Near-term debt coverage
210.3×
Passes when: Cash and short-term investments cover debt due within 12 months.
Manageable net debt
Net cash
Passes when: Net debt is below 3 times EBITDA.
Tangible equity base
0.0%
Passes when: Goodwill and intangibles are below 50% of equity.
Altman Z-score trend
2.91 → 6.91
Passes when: The Z-score is stable or rising, or stays above 2.99.
Financial strength scores
How strong are the fundamentals over time?
Piotroski tests profitability, balance-sheet direction, and efficiency; Altman estimates bankruptcy risk. Compare the current scores with their fiscal-year history.
Financial strength scores
Piotroski F-Score and Altman Z-Score from the latest reported financials
Piotroski F-Score
Weak3 / 9
Nine pass/fail tests of profitability, balance-sheet strength, and efficiency. 8–9 is strong, 0–3 is weak.
Altman Z-Score
Distress zone0.92
Bankruptcy-risk model. Above 2.99 is the safe zone, 1.81–2.99 the grey zone, and below 1.81 the distress zone.
Score history
Piotroski F-Score and Altman Z-Score recalculated from each fiscal year's statements and year-end market value.
| Score | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Piotroski F (0–9) | 2 | 2 | 4 | 2 | 6 | 3 | 3 | 4 | 4 | 4 |
| Altman Z | 1.29 | -6.37 | -5.12 | -8.33 | 1.46 | -1.07 | -5.25 | -2.45 | 2.91 | 6.91 |
Piotroski: 8–9 strong, 4–7 average, 0–3 weak. Altman: above 2.99 safe, 1.81–2.99 grey, below 1.81 distress. Our calculation can differ slightly from the provider's current scores above.
Liquidity
Can it meet short-term obligations?
Check whether cash and current assets cover what falls due within a year without depending on fresh financing.
Cash & Equivalents
$666.70M
Q1 2026
Quick Ratio
14.7x
Q1 2026
Current Ratio
14.8x
Q1 2026
Cash Ratio
14.0x
Q1 2026
Working capital
How quickly does cash come back?
Receivable, inventory, and payable days show how much cash the operating cycle ties up and whether that is changing.
Working capital and cash conversion
Annual days measures from year-end receivables, inventory, and payables against revenue and cost of revenue.
Working capital (Q1 2026)
$658.31M
Current assets − current liabilities
Days sales outstanding
216 d
+30 days vs. prior year
Days inventory outstanding
198 d
+1 days vs. prior year
Days payables outstanding
231 d
-40 days vs. prior year
Cash conversion cycle
183 d
+71 days vs. prior year
Leverage
How much debt risk sits on the balance sheet?
Review total borrowings, debt relative to equity and assets, and whether operating profit covers interest costs.
Total Debt
$79.46M
Q1 2026
Debt/Equity
0.1x
Q1 2026
Debt/Assets
0.1x
Q1 2026
Interest Coverage
—
Q1 2026
Debt service
Can cash flow carry the debt?
Measure debt against EBITDA and free cash flow, see how much is due within 12 months, and follow debt and cash over time.
Debt service capacity
Can operating cash flow carry the debt, and how much is due soon?
Net debt
Net cash: $587.24M
Total debt − cash − short-term investments
Net debt / EBITDA
Net cash
Above 3× is elevated
Free cash flow / debt
-303.2%
Share of debt one year of FCF could repay
Years to repay debt
Negative FCF
Total debt ÷ free cash flow
Operating cash flow / current liabilities
-4.7×
Above 1× funds a year of obligations
Interest coverage
-25.8×
Operating income ÷ interest expense
Debt maturity
Cash and short-term investments cover short-term debt 210.3×.
Balance sheet as of Q1 2026; cash flows TTM to Q1 2026.
Debt and cash over time
Fiscal-year-end borrowings against liquid assets; net debt below zero means net cash.
Balance sheet cushion
How much room is there if conditions weaken?
Extra cash and investments, and the balance of assets against liabilities, give the company room when trading gets harder.
Long-Term Investments
$1.61M
Q1 2026
Assets
$732.53M
Q1 2026
Liabilities
$150.96M
Q1 2026
Balance sheet quality
Who funds the assets, and how tangible is the equity?
Split the claims on assets between suppliers, lenders, customers, and shareholders, and see how much equity rests on goodwill and intangibles.
Balance sheet quality
Who funds the assets, and how much of the equity is tangible (Q1 2026).
Claims on $732.53M in assets
- Payables1.1%
- Short-term debt0.4%
- Long-term debt9.8%
- Deferred revenue1.9%
- Other liabilities7.3%
- Equity79.4%
Goodwill + intangibles
$0
0.0% of total assets
Share of equity
0.0%
Above 50% leaves little tangible backing
Tangible equity
$581.57M
Equity left after writing off goodwill and intangibles
Deferred revenue
$14M
Customer prepayments: a liability settled by delivering service, not cash
Competitor health
How does Ocular Therapeutix, Inc. compare with peers?
Compare leverage, interest coverage, and liquidity ratios with similar companies.
Competitor Health
Peer financial health comparison
| Company | Market Cap | D/E | D/Assets | ND/EBITDA | Int. Cov. | Quick | Current | Cash |
|---|---|---|---|---|---|---|---|---|
Glaukos Corporation GKOS:NYSE | $14.55B | 0.21 | 0.16 | Net cash | — | 4.06 | 4.69 | 0.90 |
Bausch + Lomb Corporation BLCO:NYSE | $7.54B | 0.83 | 0.38 | 9.32 | 0.44 | 1.04 | 1.55 | 0.20 |
Kodiak Sciences Inc. KOD:NASDAQ | $6.99B | 1.01 | 0.45 | 0.25 | — | 4.72 | 4.72 | 4.61 |
STAAR Surgical Company STAA:NASDAQ | $1.32B | 0.11 | 0.08 | 1.56 | — | 3.74 | 4.55 | 2.24 |
Harrow Health, Inc. HROW:NASDAQ | $1.13B | 4.80 | 0.63 | 4.33 | 1.60 | 2.06 | 2.20 | 0.76 |
SpyGlass Pharma, Inc. Common Stock SGP:NASDAQ | $1.10B | -0.02 | 0.01 | 2.41 | — | 12.67 | 12.67 | 11.23 |
Oculis Holding AG OCS:NASDAQ | $471.63M | 0.01 | 0.01 | 0.85 | — | 5.96 | 5.96 | 2.21 |
Ocugen, Inc. OCGN:NASDAQ | $280.88M | -2.72 | 0.76 | Net cash | — | 1.06 | 1.06 | 0.81 |
Outlook Therapeutics, Inc. OTLK:NASDAQ | $100.54M | -0.94 | 1.62 | Net cash | — | 0.31 | 0.38 | 0.18 |
EyePoint Pharmaceuticals, Inc. EYPT:NASDAQ | $25.66M | 0.07 | 0.06 | 0.35 | 7376.79 | 8.83 | 8.88 | 2.75 |
Questions
Financial health questions
Common questions about OCUL's balance sheet, answered from the reported figures.
Is OCUL's balance sheet healthy?
Ocular Therapeutix, Inc. (OCUL) has a current ratio of 14.81, a quick read on short-term liquidity.
How leveraged is OCUL?
Debt to equity is 0.14, which helps judge how much financing risk sits on the balance sheet.
Continue the stock analysis
Jump to another research area for this company.